|
27 Nov 2020 |
AbbVie and Eisai Announce an approval for additional indication of HUMIRA®, a fully Human Anti-TNFα Monoclonal Antibody, for the treatment of pyoderma gangrenosum for the first time in the world
|
|
27 Nov 2020 |
Vertex Announces European Commission Approval for SYMKEVI® (tezacaftor/ivacaftor) With KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 6-11 Years
|
|
26 Nov 2020 |
European Medicines Agency Validates Application for Tepotinib for the Treatment of Advanced NSCLC with METex14 Skipping Alterations
|
|
26 Nov 2020 |
Altimmune Announces Submission of Investigational New Drug Application for AdCOVID™ a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence Phase 1 Clinical Study in December
|
|
26 Nov 2020 |
FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma
|
|
26 Nov 2020 |
Karyopharm Announces Ongoing Phase 3 SIENDO Study of XPOVIO® (Selinexor) in Patients with Endometrial Cancer Passes Planned Interim Futility Analysis: Data and Safety Monitoring Board Recommends the Study Should Proceed as Planned Without Any Modification
|
|
26 Nov 2020 |
Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations
|
|
26 Nov 2020 |
Celltrion completes enrolment for global Phase II clinical trial with COVID-19 treatment candidate CT-P59
|
|
26 Nov 2020 |
Bio-Thera Solutions Submits Marketing Authorization Application (MAA) for BAT1706, a Proposed Biosimilar to Avastin®, to European Medicines Agency (EMA)
|
|
26 Nov 2020 |
COVAXX Announces $2.8 Billion in Advance Purchase Commitments to Deliver More Than 140 Million Vaccine Doses to Emerging Countries
|
|
25 Nov 2020 |
Integral Molecular Announces Best-in-Class Antibodies Against Complex Oncology Target Claudin 18.2
|
|
25 Nov 2020 |
F-star Therapeutics Announces Clearance of Clinical Trial Application for FS222
|
|
25 Nov 2020 |
European Commission Approves Janssen’s TREMFYA (guselkumab), a First-in-Class Treatment for Active Psoriatic Arthritis (PsA)
|
|
25 Nov 2020 |
Celularity Announces Dosing of First Patient in Phase I Study of Human Placental Hematopoietic Stem Cell-Derived Natural Killer Cells (CYNK-001) in Adults with Recurrent Glioblastoma Multiforme and E-Poster Presentation at the Society for Neuro-Oncology
|
|
25 Nov 2020 |
Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary Endpoint
|
|
25 Nov 2020 |
Genmab Announces Enapotamab Vedotin Update
|
|
24 Nov 2020 |
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
|
|
24 Nov 2020 |
City of Hope Initiates Phase 1 Clinical Trial to Test Its First SARS-CoV-2 Investigational Vaccine
|
|
24 Nov 2020 |
Alnylam Announces U.S. Food and Drug Administration (FDA) Approval of OXLUMO™ (lumasiran), the First and Only Treatment Approved for Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels in Pediatric and Adult Patients
|
|
24 Nov 2020 |
GSK starts phase 3 study of RSV maternal candidate vaccine
|
